Clinical Trials Logo

Severe Preeclampsia clinical trials

View clinical trials related to Severe Preeclampsia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06265415 Not yet recruiting - Severe Preeclampsia Clinical Trials

Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine

Start date: March 30, 2024
Phase: N/A
Study type: Interventional

Pre-eclampsia (PE) is one of the most frequent pregnancy complications and is one of the main causes of maternal and fetal morbidity and mortality in its severe form.control of blood pressure is of crucial importance to avoid maternal and fetal complications.Therapeutic modalities that can target the underlying pathophysiological changes and reverse the endothelial dysfunction could help to ameliorate the systemic manifestations in patients with severe PE. Either Intravenous labetalol and nitroglycerine as well as sublingual nifedipine have been frequantly used for the management of acute severe hypertension in PE

NCT ID: NCT01538121 Not yet recruiting - Clinical trials for Antiphospholipid Syndrome

Antiphospholipid Antibodies and Early Severe Preeclampsia.

Start date: June 2015
Phase: N/A
Study type: Observational

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of severe preeclampsia before 34 weeks of gestation, but this was done without solid evidence of a relation between the two. Our study will try to add information to this particular point.